AARD News
Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?
Agilent Technologies gears up for Q4 fiscal 2026 earnings, with revenues and EPS growth expected amid strength in chromatography, spectroscopy and consumables.
Zacks
Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?
Agilent Technologies gears up for Q4 fiscal 2026 earnings, with revenues and EPS growth expected amid strength in chromatography, spectroscopy and consumables.
Zacks
Aardvark Therapeutics Stock Surges as FDA Lifts Clinical Hold After Cardiac Safety Concerns
Aardvark Therapeutics shares jumped 25.06% after hours as the FDA lifted its clinical hold on ARD-101 development.read more...
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million.
Aardvark Therapeutics (NASDAQ:AARD) stockread more...
Benzinga
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action...
Business Wire
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ --Why: Rosen...
PR Newswire
AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitPR NewswireSAN...
PR Newswire
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARDPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026...
PR Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 12, 2026LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Schall...
PR Newswire
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action LawsuitPR NewswireSAN FRANCISCO, Oct. 8, 2026SAN FRANCISCO...
PR Newswire